KIT
MOLECULAR TARGETKIT proto-oncogene, receptor tyrosine kinase
KIT (KIT proto-oncogene, receptor tyrosine kinase) is targeted by 9 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting KIT
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Sorafenib | 3.66 | 38 |
| 2 | Axitinib | 3.22 | 24 |
| 3 | Avapritinib | 2.83 | 16 |
| 4 | Dasatinib | 2.30 | 9 |
| 5 | Crizotinib | 1.10 | 2 |
| 6 | Imatinib Mesylate | 1.10 | 2 |
| 7 | pd98059 | 0.69 | 1 |
| 8 | N-pyridazin-3-yl-4-(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzylidene)piperidine-1-carboxamide [Supplementary Concept] | 0.69 | 1 |
| 9 | sp600125 | 0.69 | 1 |
About KIT as a Drug Target
KIT (KIT proto-oncogene, receptor tyrosine kinase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 9 compounds with documented KIT interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
KIT inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.